Reynders McVeigh Capital Management LLC Grows Stock Holdings in Relx Plc (NYSE:RELX)

Reynders McVeigh Capital Management LLC grew its stake in shares of Relx Plc (NYSE:RELX) by 13.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 560,733 shares of the technology company’s stock after acquiring an additional 65,729 shares during the period. Relx accounts for approximately 1.3% of Reynders McVeigh Capital Management LLC’s portfolio, making the stock its 29th largest holding. Reynders McVeigh Capital Management LLC’s holdings in Relx were worth $25,469,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in RELX. JPMorgan Chase & Co. grew its stake in Relx by 14.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 826,481 shares of the technology company’s stock worth $39,225,000 after buying an additional 104,999 shares in the last quarter. LGT Group Foundation purchased a new position in Relx in the 4th quarter worth approximately $257,000. Paradigm Asset Management Co. LLC boosted its position in Relx by 17.1% during the 4th quarter. Paradigm Asset Management Co. LLC now owns 81,600 shares of the technology company’s stock valued at $3,706,000 after buying an additional 11,900 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Relx by 120.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 12,066 shares of the technology company’s stock worth $548,000 after purchasing an additional 6,588 shares during the last quarter. Finally, Merit Financial Group LLC purchased a new position in shares of Relx during the fourth quarter valued at approximately $301,000. Hedge funds and other institutional investors own 15.02% of the company’s stock.

Relx Stock Up 0.1 %

NYSE:RELX opened at $49.06 on Friday. The firm has a 50-day simple moving average of $49.29 and a two-hundred day simple moving average of $47.87. The firm has a market cap of $90.79 billion, a P/E ratio of 26.37, a P/E/G ratio of 2.73 and a beta of 0.84. Relx Plc has a fifty-two week low of $40.25 and a fifty-two week high of $51.99. The company has a debt-to-equity ratio of 1.46, a quick ratio of 0.47 and a current ratio of 0.52.

Relx Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Wednesday, June 25th. Investors of record on Friday, May 9th will be given a dividend of $0.5586 per share. This is an increase from Relx’s previous semi-annual dividend of $0.23. The ex-dividend date of this dividend is Friday, May 9th. This represents a yield of 1.6%. Relx’s dividend payout ratio is 59.68%.

Analysts Set New Price Targets

A number of research analysts have recently commented on RELX shares. The Goldman Sachs Group assumed coverage on Relx in a research note on Wednesday, March 26th. They issued a “buy” rating for the company. StockNews.com lowered shares of Relx from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Redburn Atlantic assumed coverage on shares of Relx in a research note on Wednesday, January 8th. They set a “buy” rating for the company. Finally, Barclays upgraded Relx from an “equal weight” rating to an “overweight” rating in a research note on Friday, March 14th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Relx currently has a consensus rating of “Buy”.

About Relx

RELX Plc engages in provision of information and analytics solutions for professional and business customers across industries. It operates through the following business segments: Scientific, Technical & Medical; Risk & Business Analytics; Legal; and Exhibitions. The Scientific, Technical & Medical segment is a global information analytics business that helps institutions and professionals advance healthcare, open science, and improve performance for the benefit of humanity.